Evotec to Report First Quarter Results on 14 May 2013

Evotec to Report First Quarter Results on 14 May 2013

HAMBURG, Germany, May 7, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (ISIN:DE0005664809) will report its financial results for the first
quarter of 2013 on Tuesday, 14 May 2013.

The Company is going to hold a conference call to discuss the results as well
as to provide an update on its performance:

Conference call details

Date:          Tuesday, 14 May 2013
Time:          09.30 am CET (08.30 am BST, 3.30 am EDT)
              
              
From Germany: +49 (0) 6103 485 3001
From UK:      +44 207 153 2027
From USA:     +1 480 629 9673
Access Code:  4615712

A simultaneous slide presentation for participants dialling in via phone is
available at www.equitystory.com, password: evotec1112.

Webcast details

To join the audio webcast and to access the presentation slides you will find
a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialling +49 69 58 99 90 568 (Germany) or +44 207 959
6720 (UK) and in the US by dialling +1 303 590 3030. The access code is
4615712#. The on-demand version of the webcast will be available on our
website:
http://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2011-2013/188/6/26.

About Evotec AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
 
Press spacebar to pause and continue. Press esc to stop.